Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) said the top-line results from its successful phase III study will be run as a late-breaking abstract at the European Association of Dermatology and Venereology Virtual Congress later this month.
The EASE trial of FILSUVEZ showed the gel was effective in accelerating wound healing in people with epidermolysis bullosa, a rare, chronic and distressing genetic skin disorder.
The treatment has been granted rare paediatric disease designation and has also been given fast track status by the US Food and Drug Administration.
Amryt’s oral presentation will take place on October 31, 2020.
For more details click here.